The moat in interventional psychiatry has moved from the molecule to the chair

The bottleneck in interventional psychiatry is no longer the compound. It is the chair. Once a treatment-resistant depression drug has to be dosed in a certified clinic under a REMS program, the constraint becomes how many patients each room, nurse, and two-hour monitoring window can rotate through in a day. Johnson & Johnson built that clinic network for Spravato and now sits on a real asset: not the molecule esketamine, but the two-hour slot inside the Spravato clinic footprint.

Eli Lilly's $2.8 billion purchase of AtaiBeckley is a chair-economics wager on a faster BPL-003 session that can run more turns on the same infrastructure. AtaiBeckley CEO Srinivas Rao made the model explicit at the company's March 2026 investor day: take the lessons from Spravato and "design treatments that retain or possibly even improve upon efficacy while dramatically reducing complexity." Compress the session, keep the clinic, harvest the throughput. The Phase 2b observation that most BPL-003 patients are ready for discharge after roughly 90 minutes is the load-bearing number.

A shorter chair cycle compounds across J&J's existing footprint. The bet is conditional. BPL-003 is not approved, the 90-minute discharge has not survived Phase 3, and roughly a third of the headline value sits behind a DEA rescheduling decision on 5-MeO-DMT. If the chair math holds, Spravato's clinic moat is also BPL-003's clinic moat, and the company that built it just paid the entry fee to be undercut on its own floor.